Los Angeles Capital Management LLC I Teos Therapeutics, Inc. Transaction History

Los Angeles Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	SELL	$10.33 - $18.09 $41,320 - $72,360	-4,000 Reduced 13.61%	25,398 $376,000
Q1 2024 Apr 05, 2024	BUY	$9.89 - $13.64 $290,746 - $400,988	29,398 New	29,398 $400,000
Q3 2023 Nov 06, 2023	SELL	$10.95 - $14.6 $48,924 - $65,232	-4,468 Reduced 4.06%	105,554 $1.16 Million
Q2 2023 Aug 03, 2023	BUY	$12.93 - $18.05 $36,204 - $50,540	2,800 Added 2.61%	110,022 $1.46 Million
Q1 2023 May 04, 2023	BUY	$13.02 - $22.62 $247,692 - $430,322	19,024 Added 21.57%	107,222 $1.46 Million
Q4 2022 Feb 06, 2023	BUY	$17.77 - $21.6 $6,610 - $8,035	372 Added 0.42%	88,198 $1.72 Million
Q3 2022 Nov 02, 2022	SELL	$18.6 - $27.25 $687,660 - $1.01 Million	-36,971 Reduced 29.62%	87,826 $1.67 Million
Q2 2022 Aug 05, 2022	BUY	$16.57 - $35.1 $1.53 Million - $3.24 Million	92,192 Added 282.75%	124,797 $2.57 Million
Q1 2022 May 06, 2022	BUY	$31.92 - $47.45 $1.04 Million - $1.55 Million	32,605 New	32,605 $1.05 Million

165

36.5M

890K

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $301M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.